RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

On May 23, 2018, the board of directors of Ritter Pharmaceuticals, Inc. (the “Company”) appointed John W. Beck as the Company’s chief financial officer, effective May 24, 2018.

John W. Beck, age 58, served as chief financial officer and senior vice president of finance & operations of Ardea Biosciences Inc. (“Ardea”), from 2008 until its acquisition by AstraZeneca in 2012. Before joining Ardea, Mr. Beck spent 10 years with Metabasis Thereapeutics Inc., as a co-founder and its chief financial officer.

Since leaving Ardea in 2012, Mr. Beck has been serving as a board member and advisor to August Therapeutics, Inc., a San Diego California-based company developing non-systemic therapeutics to treat disordered eating and obesity, and Pinnacle Medical Holdings, LLC, a Denver Colorado-based physician-led network of health-care providers, which was acquired by OnPoint Medical Group, LLC in August 2017. Mr. Beck holds a Bachelor’s degree in Accounting from the University of Washington, Seattle and a Bachelor’s degree in Theology from a Seattle-area seminary.

The Company entered into an offer letter with Mr. Beck on May 23, 2018 (the “Offer Letter”). to the terms of the Offer Letter, Mr. Beck’s annual base salary will be $320,000. He will also be eligible to receive a target annual bonus equal to 40% of his base salary, as then in effect, as determined by the board of directors, and will receive reimbursement in an amount up to $2,000 per month for reasonable travel and housing expenses in connection with his commute to Los Angeles, the Company’s headquarters. Mr. Beck will also be eligible to participate in all employee benefit programs generally available to other executive level employees of the Company.

to the terms of the Offer Letter, on May 23, 2018, the board of directors granted Mr. Beck a stock option to purchase 100,000 shares of the Company’s common stock, of which 25% of the shares will vest on May 24, 2019, with the remaining shares vesting in 36 equal monthly installments beginning on the 24th day of each calendar month after May 24, 2019. The exercise price of the option is $3.32 per share, the closing price of the Company’s common stock on the date of grant.

The Company also entered into an Executive Severance and Change in Control Agreement (the “Severance Agreement”) with Mr. Beck, effective as of May 24, 2018.

The Severance Agreement provides that if after the six month anniversary of the date on which Mr. Beck’s employment with the Company commences, the Company terminates his employment without Cause (as defined in the Severance Agreement) or Mr. Beck terminates his employment for Good Reason (as defined in the Severance Agreement), Mr. Beck will be entitled to: (i) his earned but unpaid base salary through the termination date, payment of any annual, long-term, or other incentive award which relates to a completed fiscal year or performance period, as applicable, that is payable (but not yet paid) on or before the termination date, a lump-sum payment in respect of accrued but unused vacation days at Mr. Beck’s per-business-day base salary rate in effect as of the termination date, and any unpaid expense or other reimbursement due to Mr. Beck to the Company’ expense reimbursement policy (the “Accrued Obligations”); (ii) an amount equal to six months of Mr. Beck’s base salary as in effect immediately prior to the termination date; and (iii) medical, dental benefits until the earlier of (a) the six month anniversary of the termination date or (b) the date Mr. Beck becomes covered under a subsequent employer’s medical and dental plans.

The Severance Agreement also provides that in the event that within one month prior to or the 12 months following a Change in Control (as defined in the Severance Agreement) the Company terminates Mr. Beck’s employment without Cause or Mr. Beck terminates his employment with Good Reason, then, in lieu of the payments and benefits described in the preceding paragraph, Mr. Beck will be entitled to: (i) the Accrued Obligations; (ii) an amount equal to the sum of six months of this base salary as in effect on the termination date or the date of the Change in Control, whichever is greater; (iii) medical, dental benefits until the earlier of (a) the six month anniversary of the termination date or (b) the date Mr. Beck becomes covered under a subsequent employer’s medical and dental plans; and (iv) acceleration of vesting of all equity and equity-based awards granted to Mr. Beck.

Mr. Beck’s entitlement to the payments (other than the Accrued Obligations) and benefits under the Severance Agreement as described above are expressly contingent upon his providing the Company with a signed release satisfactory to the Company.

The foregoing description of the Offer Letter and the Severance Agreement is not complete and is qualified in its entirety by reference to the full text of the Offer Letter and the Severance Agreement, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K (this “Report”) and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On May 29, 2018, the Company issued a press release announcing the appointment of Mr. Beck as chief financial officer of the Company. A copy of the press release is attached as Exhibit 99.1 to this Report and is incorporated herein by reference.

The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall the information in this Item 7.01 (including Exhibit 99.1 attached hereto) be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


RITTER PHARMACEUTICALS INC Exhibit
EX-10.1 2 ex10-1.htm   Exhibit 10.1     May 23,…
To view the full exhibit click here

About RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

An ad to help with our costs